A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants
Completed · Phase 1 · NCT06315335
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $1,314
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- UCB9741 (drug), Placebo (drug)
- Dates
- Started 2024-07-01; completion 2025-01-01
- Results posted
- Not yet
The purpose of the study is investigate the safety, tolerability and pharmacokinetic of UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy Caucasian and Japanese participants.
From ClinicalTrials.gov, last updated 2025-11-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $1,314 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.